Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 80 Forward PE Ratio is 250.00 as of Jul. 17, 2026. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.06 (Fairly Valued). The stock has 1 warning sign investors should review. Among 313 Healthcare Providers & Services companies, Diaceutics ranks worse than 96.17% on this metric.
Diaceutics's Forward PE Ratio for today is 250.00.
Diaceutics (OTCPK:DIUXF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Diaceutics Forward PE Ratio Related Terms
Diaceutics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Diaceutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics Forward PE Ratio Chart
Diaceutics Annual Data
Trend
2021-12
2024-12
2025-12
Forward PE Ratio
33.00
52.58
26.81
Diaceutics Semi-Annual Data
2020-06
2021-06
2021-12
2024-12
2025-06
2025-12
Forward PE Ratio
156.25
128.21
33.00
52.58
56.97
26.81
DIUXF vs VEEV, BTSG, TEM: Forward PE Ratio Comparison
For the Health Information Services subindustry, Diaceutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Diaceutics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Diaceutics (DIUXF) has a Forward PE Ratio of 250.00 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Diaceutics and its competitors. According to the industry distribution chart, Diaceutics ranks #301 out of 313 companies in the Healthcare Providers & Services industry, placing it in the top 96.2%.
Is Diaceutics' Forward PE Ratio too high?
Diaceutics' current Forward PE Ratio is 250.00. The Healthcare Providers & Services industry median Forward PE Ratio is 18.66. Diaceutics' value of 250.00 is 1239.8% above this industry median. Based on the distribution chart, Diaceutics ranks #301 out of 313 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Forward PE Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #301 out of 313 companies for Forward PE Ratio. This places Diaceutics in the lower half of its industry. The industry median Forward PE Ratio is 18.66. Diaceutics' value of 250.00 is 1239.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.66, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current Forward PE Ratio of 250.00 is 1239.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current Forward PE Ratio is 250.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.06, compared to a current price of $2.00 — trading 2.9% below its estimated fair value. The current Forward PE Ratio is 250.00 and 1239.8% above the Healthcare Providers & Services industry median of 18.66. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Diaceutics (DIUXF), the current Forward PE Ratio is 250.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 2.9% below its estimated GF Value™ of $2.06.
GuruFocus considers Diaceutics to be Fairly Valued.
Key valuation signals for DIUXF:
Forward PE Ratio: 250.00
GF Value™: $2.06 vs. price of $2.00 (2.9% below fair value)
Industry Position: 1239.8% above the Healthcare Providers & Services median (#301 of 313)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score
Get the complete analysis for DIUXF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
